Journal of Rheumatology最新文献

{"title":"The Effect of Area-Level Socioeconomic Status on Disease Outcomes in Rheumatoid Arthritis: Results From an Australian Longitudinal Inception Cohort Study.","authors":"Oscar Russell, Susan Lester, Jessica Stanhope, Kim Griggs, Leah McWilliams, Anita Lee, Susanna Proudman, Rachel J Black, Catherine L Hill","doi":"10.3899/jrheum.2025-0869","DOIUrl":"10.3899/jrheum.2025-0869","url":null,"abstract":"<p><strong>Objective: </strong>Socioeconomic status (SES) is associated with differences in health outcomes for individuals with rheumatoid arthritis (RA). We aimed to determine the effect of area-level SES on RA disease activity, disability, quality of life (QOL), and biologic/targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) use in individuals with early RA managed within a protocolized, treat-to-target (T2T), longitudinal observational cohort study.</p><p><strong>Methods: </strong>Adult patients with RA diagnosed after June 2003 were included. SES was defined as quintiles of Index of Relative Social Advantage and Disadvantage (IRSAD) based on residential address at baseline. Covariates included baseline age, sex, smoking status, BMI, and the Rheumatic Disease Comorbidity Index (RDCI). Longitudinal multivariable random effects regression models were constructed with restricted cubic splines examining nonlinear responses in outcome variables. b/tsDMARD use was examined using time-to-event models for recurrent events.</p><p><strong>Results: </strong>Of 255 participants, 66.7% were female, with mean age 53.9 years, and 68% had seropositive disease. There was an ordered trend across SES quintiles, such that higher quintiles were associated with lower Disease Activity Score in 28 joints based on C-reactive Protein (DAS28-CRP; <i>P</i> = 0.03), lower modified Health Assessment Questionnaire (mHAQ; <i>P</i> = 0.001), and higher 36-item Short Form Health Survey physical component summary (SF-36 PCS; <i>P</i> < 0.001). SES quintile was not significantly associated with b/tsDMARD initiation or switching.</p><p><strong>Conclusion: </strong>Disadvantageous SES was associated with higher disease activity, disability, and poorer QOL. Our results suggest an inequity in health outcomes for patients with RA despite T2T management within a universal healthcare system.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"501-509"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146203568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Rates of Degenerative Changes in the Lower Spine in Calcium Pyrophosphate Deposition Disease Compared to Degenerative Disc Disease.","authors":"Kalliopi Klavdianou, David Kiefer, Philipp Sewerin, Styliani Tsiami, Jona Kasfeld, Jörg H W Distler, Xenofon Baraliakos","doi":"10.3899/jrheum.2025-0870","DOIUrl":"10.3899/jrheum.2025-0870","url":null,"abstract":"<p><strong>Objective: </strong>To assess the effect of calcium pyrophosphate deposition disease (CPPD; chondrocalcinosis) on the axial skeleton and compare it with degenerative disc disease (DDD).</p><p><strong>Methods: </strong>Conventional radiographs (CR) and magnetic resonance imaging (MRI) of patients with CPPD or DDD were retrospectively assessed by 2 independent readers for vacuum phenomena, disc calcification, endplate erosion, osteophytes, disc height changes, and spondylolisthesis. Available follow-up CR were assessed.</p><p><strong>Results: </strong>CR from 140 patients with CPPD (1171 discovertebral units [DVU]) and 99 with DDD (803 DVU) were evaluated (mean [SD] age 74.4 [9.9] vs 71 [6.2] years; 20% vs 20.2% male individuals, respectively). Disc calcification, osteophytes, and erosions were noted significantly more frequently in CPPD vs DDD (16.5% vs 5.2%, 73.5% vs 59.8%, and 13.6% vs 3.2%, respectively; all <i>P</i> ≤ 0.002). Follow-up CR from 29 patients with CPPD and 46 with DDD were available. Significant progression of endplate erosions and osteophytes was seen (<i>P</i> ≤ 0.02) in both groups. CR follow-up in the CPPD group was shorter than that in DDD (median [IQR] 1.9 [0.6-3.0] vs 3.0 [1.6-4.7] years, respectively; <i>P</i> = 0.03), but CPPD compared with DDD showed more frequent radiographic erosive changes in the thoracic spine (6.8% vs 0.6%; <i>P</i> = 0.02) and lumbar disc calcification (5.8% vs 0.6%; <i>P</i> = 0.01).</p><p><strong>Conclusion: </strong>CPPD is associated with more severe and progressive structural changes in the lower spine compared to DDD. Differentiating CPPD from DDD has clinical implications, influencing both appropriate management strategies and clinical course estimation.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"569-574"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis.","authors":"Rebecca Fitzpatrick, Shadpour Demehri, Joseph Murray, Julie R Brahmer, Elena Ghotbi, Durrant Barasa, Clifton O Bingham, Ami A Shah, Laura C Cappelli","doi":"10.3899/jrheum.2025-0808.C1","DOIUrl":"10.3899/jrheum.2025-0808.C1","url":null,"abstract":"<p><p>J Rheumatol 2026; doi: 10.3899/jrheum.2025-0808In the originally published online version of this article, reference 8 was missing from the list of references. The missing reference has now been added: \"8. Cunningham-Bussel A, Wang J, Prisco LC, et al. Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer. Arthritis Rheumatol 2022;74:527-40.\"This correction applies only to the February 1 2026 First Release. The complete list of references appears in the print and online issues.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147693153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2nd Brazilian GRAPPA International Meeting on Psoriasis and Psoriatic Arthritis-2° Encontro Internacional do GRAPPA sobre Psoríase e Artrite Psoriásica.","authors":"Claudia Goldenstein-Schainberg, Rachel de Lima Grynszpan, Andre L Ribeiro, Valderílio F Azevedo, April W Armstrong, Philip J Mease","doi":"10.3899/jrheum.2025-1096","DOIUrl":"https://doi.org/10.3899/jrheum.2025-1096","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147693206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome-Wide Association Study Identifies Genetic Loci for Antibody Response to SARS-CoV-2 Vaccines in Patients With Systemic Autoimmune Diseases and Healthy Individuals.","authors":"Kwangwoo Kim, Dillon Claybaugh, Eduardo Patino-Martinez, Yenealem Temesgen-Oyelakin, Elaine Poncio, Jun Chu, Michael Davis, Alice Fike, Yanira Ruiz-Perdomo, Julie Onyechi, Margaret Beach, Lilian Howard, Eileen Pelayo, Nancy Spencer, Martha Sully, Rita Volochayev, Sophie Kelly, Sarah Porche, Laura B Lewandowski, Luis M Franco, Zerai Manna, Sarthak Gupta, Amy Hutchinson, Lisa Mirabello, Vibha Vij, Kaitlin A Quinn, Peter C Grayson, Adam Schiffenbauer, Lisa G Rider, Iago Pinal-Fernandez, Andrew L Mammen, Heather R Kalish, Meryl A Waldman, Blake Warner, Sarfaraz Hasni, Stephen J Chanock, Mariana J Kaplan","doi":"10.3899/jrheum.2025-0770","DOIUrl":"10.3899/jrheum.2025-0770","url":null,"abstract":"<p><strong>Objective: </strong>The efficacy of nucleic acid-based vaccines against SARS-CoV-2 varies across individuals, partly due to genetic factors influencing neutralizing antibody production. In patients with systemic autoimmune diseases (SADs), this response may be further altered by immune dysregulation.</p><p><strong>Methods: </strong>We conducted a genome-wide association study (GWAS) to identify genetic variants associated with postvaccination anti-SARS-CoV-2 IgG antibody levels and to assess whether these associations differ between patients with SAD and healthy individuals.</p><p><strong>Results: </strong>The study included 165 participants (138 with SADs, 27 healthy controls), all of whom received nucleic acid-based vaccines. Antibody levels targeting the spike protein receptor-binding domain (RBD) and nucleocapsid were measured between 1 and 12 months after vaccination. GWAS results were metaanalyzed with data from a previously published GWAS with 1076 healthy individuals. We identified a novel association near <i>RACGAP1</i> (rs706785; β_meta = -0.30, <i>P</i> _meta = 3.85 × 10^-8) and replicated a known association at HLA-DRB1 position 71 (β_meta = -0.23, <i>P</i> _meta = 1.94 × 10^-11). No significant interactions were observed between genotype and disease status.</p><p><strong>Conclusion: </strong>This study highlights both MHC and non-MHC genetic contributions to SARS-CoV-2 vaccine responses and suggests these effects are consistent across patients with SADs and healthy individuals, supporting standard vaccination strategies for individuals with systemic autoimmune conditions.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"456-462"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12866942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Acute Coronary Syndromes in Systemic Lupus Erythematosus: Are We Moving in the Right Direction?","authors":"Susan Manzi","doi":"10.3899/jrheum.2026-0067","DOIUrl":"10.3899/jrheum.2026-0067","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"356-357"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146203516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient and Rheumatologist Perspectives of the Patient Self-Administered Inflammatory Arthritis Detection Tool: Implementation Considerations, Potential Barriers, and Opportunities.","authors":"Norma K Biln, Nick Bansback, Kam Shojania, Charlyn Black, Mark J Harrison","doi":"10.3899/jrheum.2025-0926","DOIUrl":"10.3899/jrheum.2025-0926","url":null,"abstract":"<p><strong>Objective: </strong>As part of a research program examining rheumatology referrals in British Columbia, the Patient Self-Administered Inflammatory Arthritis Detection (SAID) Study evaluated the SAID tool, which contains validated patient-completed questionnaires for identifying and prioritizing individuals with inflammatory arthritis, supporting its utility and feasibility. This article reports the perspectives of participating patients and rheumatologists regarding the SAID tool.</p><p><strong>Methods: </strong>A multimethods design was used to collect and analyze patient survey and rheumatologist interview data, with an emphasis on implementation considerations. Ninety-two patients who completed the questionnaires in the Patient SAID Study also provided feedback on their experience. Semistructured interviews were conducted with 3 rheumatologists. Quantitative and qualitative data were analyzed using Microsoft Excel and NVivo to identify usability, relevance, and barriers or enablers to implementing the tool in primary-to-specialist referral.</p><p><strong>Results: </strong>Most patients found the SAID tool easy to log into (85%) and complete (82%). Across diagnostic groups, most (76%) believed it could help their general practitioner assess symptoms but emphasized the need for more nuanced response options and space for elaboration. Rheumatologists viewed the tool as brief, useful, and potentially valuable for triage, especially if integrated at the referral stage. Key barriers included time constraints, false negatives, and lack of integration with electronic medical records. All rheumatologists supported optional implementation led by motivated patients, provided it complemented-not complicated-existing workflows.</p><p><strong>Conclusion: </strong>With targeted modifications and appropriate implementation mechanisms, the SAID tool has the potential to improve the quality of referrals, support triage decision making, and address current gaps in access to rheumatology care within evolving digital health systems.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146203428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.","authors":"John D Reveille, Atul Deodhar, Paul H Caldron, Anna Dudek, Diane D Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H Leu, Elizabeth C Hsia","doi":"10.3899/jrheum.180718.C1","DOIUrl":"https://doi.org/10.3899/jrheum.180718.C1","url":null,"abstract":"<p><p>J Rheumatol 2019; doi: 10.3899/jrheum.180718 Recently, the sponsor became aware of data errors related to Bath Ankylosing Spondylitis Metrology Index (BASMI) and the University of California San Francisco (UCSF) Enthesitis Index. The ensuing tabular and in-text corrections are provided hereinafter.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab.","authors":"William Tillett, Laura C Coates, Marijn Vis, Miriam Zimmermann, Karissa Lozenski, Emmanouil Rampakakis, Enrique R Soriano, Joseph F Merola, Mohamed Sharaf, Peter Nash, Philip S Helliwell","doi":"10.3899/jrheum.2025-0695","DOIUrl":"10.3899/jrheum.2025-0695","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the validity of the 3-item visual analog scale (3VAS) and 4-item VAS (4VAS) and determine the minimal clinically important difference (MCID) and minimal detectable change (MDC) for each measure using data from 3 phase III randomized clinical trials of guselkumab in psoriatic arthritis (PsA).</p><p><strong>Methods: </strong>Pooled data (1405 participants) from the DISCOVER-1, DISCOVER-2, and COSMOS studies were used. 3VAS/4VAS MCID and MDC were estimated using established formulas. Receiver-operating characteristic curve analysis was used to identify 3VAS/4VAS thresholds for low, moderate, and high disease activity. Criterion validity was assessed by correlating 3VAS/4VAS with other PsA measures. Mixed models evaluated the association between changes from baseline in 3VAS/4VAS at week 8 of guselkumab treatment with the total PsA-modified Sharp-van der Heijde (SvdH) score through week 100.</p><p><strong>Results: </strong>3VAS/4VAS showed moderate-to-strong correlation with all outcome measures assessed, with coefficients ranging from 0.56/0.62 for Health Assessment Questionnaire-Disability Index to 0.92/0.94 for patient global assessment. MCID was 0.9 for both 3VAS (range 0.7-1.3 depending on method used) and 4VAS (0.6-1.3); MDC was 3.1 and 3.0, respectively. 3VAS cutoffs for low, moderate, and high disease activity were 2.1, 3.3, and 4.8, respectively, and 2.1, 3.4, and 5.0 for 4VAS. Change in 4VAS at week 8 of guselkumab treatment significantly associated with change in SvdH score through week 100 (<i>P</i> = 0.04).</p><p><strong>Conclusion: </strong>These analyses support the validity of 3VAS/4VAS as multidimensional measures of PsA disease activity. 4VAS may be preferred owing to its greater face validity and separate measurements of the 2 cardinal aspects of PsA (joint/skin disease) and pain.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"400-408"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145656348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classification of Nonsystemic Juvenile Idiopathic Arthritis Using the Provisional Paediatric Rheumatology International Trials Organisation Criteria.","authors":"Mehmet Yildiz, Elif Kilic Konte, Esma Aslan, Nergis Akay, Hakan Demir, Aybuke Gunalp, Fatih Haslak, Umit Gul, Ece Aslan, Sezgin Sahin, Amra Adrovic, Kenan Barut, Ozgur Kasapcopur","doi":"10.3899/jrheum.2025-0551","DOIUrl":"10.3899/jrheum.2025-0551","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to retrospectively evaluate the provisional Paediatric Rheumatology International Trials Organisation (PRINTO) criteria in patients with juvenile idiopathic arthritis (JIA) classified according to the International League of Associations for Rheumatology (ILAR) criteria.</p><p><strong>Methods: </strong>This retrospective cohort study was conducted at a single tertiary pediatric rheumatology center. In total, 310 patients with nonsystemic JIA were classified according to both ILAR and provisional PRINTO criteria. Demographic, clinical, and laboratory features were recorded, and the distribution of JIA categories under both classification systems was analyzed.</p><p><strong>Results: </strong>The mean age at study enrollment was 169.8 (SD 59.2) months. Using ILAR criteria, 136 patients (43.9%) were categorized as having oligoarticular JIA, 73 (23.5%) enthesitis-related arthritis, 34 (11%) rheumatoid factor (RF)-negative polyarticular JIA, 12 (3.9%) psoriatic arthritis (PsA), 7 (2.3%) RF-positive polyarticular JIA, and 48 (15.5%) undifferentiated JIA. The provisional PRINTO criteria classified 107 (34.5%) patients with early-onset antinuclear antibody-positive JIA, 93 (30%) other JIA, 88 (28.4%) enthesitis/spondylitis-related JIA, 17 (5.5%) RF-positive JIA, and 5 (1.6%) unclassified JIA. The other JIA category included 93 patients, consisting of those with oligoarticular JIA (54.8%), RF-negative polyarticular JIA (21.5%), undifferentiated JIA (11.8%), enthesitis-related arthritis (6.5%), and PsA (5.4%) under the ILAR classification system.</p><p><strong>Conclusion: </strong>The provisional PRINTO criteria successfully reclassified a substantial proportion of previously undifferentiated JIA cases, improving diagnostic categorization by addressing some ILAR classification limitations. However, the high number of patients in the other JIA group highlights a potential limitation of the new system, warranting further investigation.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}